Rani Therapeutics Holdings, Inc.

Welcome to the Ronnie fourth quarter and full year 2024 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, Ronnie will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would ask for a limit of one question and one follow-up question per person. To ask a question at that time, please press star followed by 11 on your touchtone phone. If anyone has difficulty hearing the conference call, please press star zero for operator assistance. As a reminder, this call is being recorded today, March 31st, 2025. I would now like to turn the conference over to Kiki Patel at Gilmartin Group.

Please go ahead.

Thank you operator. Please turn to slide 2. Joining us on the call today from Rani Therapeutics, our Chief Executive Officer, Talat Imran and Chief Financial Officer, Svay Sanford. During this conference call, management will make forward looking statements that are subject to risks, uncertainties and assumptions, such as, but not limited to those discussed in the risk factors section of the company's filings with the Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q, which identify specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These statements may include, without limitation, statements regarding product development and clinical trials, product potential, market sizes, platform progress, platform potential, certain business strategies, capital resources, financing plans, or operating performance. Actual results and the timing of events could differ materially from those projected in such forward-looking statements. With that, I turn the call over to slide three and introduce to you Talat Imran, Chief Executive Officer of Ronnie Therapeutics. Talat?